194 related articles for article (PubMed ID: 29632319)
21. Therapeutic strategies for the treatment of neuroblastoma.
Izbicka E; Izbicki T
Curr Opin Investig Drugs; 2005 Dec; 6(12):1200-14. PubMed ID: 16370386
[TBL] [Abstract][Full Text] [Related]
22. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
23. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
Paffhausen T; Schwab M; Westermann F
Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
[TBL] [Abstract][Full Text] [Related]
24. Molecular mechanisms and therapeutic targets in neuroblastoma.
Johnsen JI; Dyberg C; Fransson S; Wickström M
Pharmacol Res; 2018 May; 131():164-176. PubMed ID: 29466695
[TBL] [Abstract][Full Text] [Related]
25. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
Zhong ZY; Shi BJ; Zhou H; Wang WB
J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
[TBL] [Abstract][Full Text] [Related]
26. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
27. Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S; Cheung NK
Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.
Chaix J; Schleiermacher G; Corradini N; André N; Thebaud E; Gambart M; Defachelles AS; Entz-Werle N; Chastagner P; De Carli É; Ducassou S; Landman-Parker J; Adam-de-Beaumais T; Larive A; Michiels S; Vassal G; Valteau-Couanet D; Geoerger B; Berlanga P
Eur J Cancer; 2024 Apr; 201():113923. PubMed ID: 38377775
[TBL] [Abstract][Full Text] [Related]
29. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.
Ham J; Costa C; Sano R; Lochmann TL; Sennott EM; Patel NU; Dastur A; Gomez-Caraballo M; Krytska K; Hata AN; Floros KV; Hughes MT; Jakubik CT; Heisey DA; Ferrell JT; Bristol ML; March RJ; Yates C; Hicks MA; Nakajima W; Gowda M; Windle BE; Dozmorov MG; Garnett MJ; McDermott U; Harada H; Taylor SM; Morgan IM; Benes CH; Engelman JA; Mossé YP; Faber AC
Cancer Cell; 2016 Feb; 29(2):159-72. PubMed ID: 26859456
[TBL] [Abstract][Full Text] [Related]
30. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ
Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773
[TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapy of neuroblastoma.
George RE; Diller L; Bernstein ML
Expert Opin Pharmacother; 2010 Jun; 11(9):1467-78. PubMed ID: 20408767
[TBL] [Abstract][Full Text] [Related]
32. Neuroblastoma-Telomere maintenance, deregulated signaling transduction and beyond.
Stainczyk SA; Westermann F
Int J Cancer; 2022 Mar; 150(6):903-915. PubMed ID: 34636058
[TBL] [Abstract][Full Text] [Related]
33. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
34. Advances in emerging drugs for the treatment of neuroblastoma.
Berlanga P; Cañete A; Castel V
Expert Opin Emerg Drugs; 2017 Mar; 22(1):63-75. PubMed ID: 28253830
[TBL] [Abstract][Full Text] [Related]
35. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
37. Recent progress in systemic treatment for lung cancer.
Clark JW; Longo DL
Curr Opin Pulm Med; 2018 Jul; 24(4):355-366. PubMed ID: 29697418
[TBL] [Abstract][Full Text] [Related]
38. Crizotinib-induced erosive esophagitis in a pediatric patient with neuroblastoma.
Lubcke N; Van Camp K
J Oncol Pharm Pract; 2019 Apr; 25(3):724-726. PubMed ID: 29357780
[TBL] [Abstract][Full Text] [Related]
39. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
Kushner BH; Cheung NV; Modak S; Becher OJ; Basu EM; Roberts SS; Kramer K; Dunkel IJ
Int J Cancer; 2017 Jan; 140(2):480-484. PubMed ID: 27649927
[TBL] [Abstract][Full Text] [Related]
40. ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.
Ueda T; Nakata Y; Yamasaki N; Oda H; Sentani K; Kanai A; Onishi N; Ikeda K; Sera Y; Honda ZI; Tanaka K; Sata M; Ogawa S; Yasui W; Saya H; Takita J; Honda H
Oncogene; 2016 Aug; 35(34):4447-58. PubMed ID: 26829053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
